Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные онкомаркеры в дифференциальной диагностике опухолей яичников вне и во время беременности (обзор литературы)
Современные онкомаркеры в дифференциальной диагностике опухолей яичников вне и во время беременности (обзор литературы)
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Обзор литературы посвящен оценке информативности современных онкомаркеров и их комбинаций в дифференциальной диагностике доброкачественных и злокачественных образований яичников вне и во время беременности.
Ключевые слова: онкомаркеры, опухоли и опухолевидные образования яичников, доброкачественные опухоли яичников, рак яичников, пограничные опухоли яичников, дифференциальная диагностика, беременность.
Key words: serum biomarkers, differential diagnosis, adnexal masses, benign ovarian masses, borderline ovarian tumors, ovarian carcinoma, pregnancy.
Ключевые слова: онкомаркеры, опухоли и опухолевидные образования яичников, доброкачественные опухоли яичников, рак яичников, пограничные опухоли яичников, дифференциальная диагностика, беременность.
________________________________________________
Key words: serum biomarkers, differential diagnosis, adnexal masses, benign ovarian masses, borderline ovarian tumors, ovarian carcinoma, pregnancy.
Полный текст
Список литературы
1. Адамян Л.В., Мурашко Л.Е., Романова Е.Л. Хирургическое лечение опухолей и опухолевидных образований яичников у беременных с использованием современных технологий. Проблемы репродукции. 2005; 3: 60–4.
2. Алексеева М.Л., Гусарова Е.В., Муллабаева С.М., Понкратов Т.С. Онкомаркеры, их характеристика и некоторые аспекты клинико-диагностического использования. Проблемы репродукции. 2005; 3: 43–5.
3. Ашрафян Л.А., Киселев В.И. Опухоли репродуктивной системы (этиология, патогенез). М.: Димитрейд График Групп, 2007.
4. Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина, 1989.
5. Ильина Л.М. Рак яичников: новое в диагностике и лечении. Информационное письмо ассоциации гинекологов-эндокринологов России №11 от 30.04.2011.
6. Краснопольский В.И., Логутова Л.С., Буянова С.Н. и др. Хирургическая и акушерская тактика при сочетании беременности с опухолями половых органов. Акуш. и гинекол. 2002; 5: 41–5.
7. Магнитская Н.А. Диагностика и лечение образований яичников у беременных. Автореф. дис. ... канд. мед. наук. М., 2012.
8. Савельева Г.М., Бреусенко В.Г., Соломатина А.А. Диагностика опухолей и опухолевидных образований яичников. Рос. вестн. акушера-гинеколога. 2005; 6: 53–61.
9. Серов В.Н., Кудрявцева Л.И. Доброкачественные опухоли и опухолевидные образования яичников. М: Триада-Х, 1999; 149.
10. Урманчеева А.Ф., Кутушева Г.Ф., Ульрих Е.А. Опухоли яичника (клиника, диагностика и лечение). СПб.: Н-Л, 2012.
11. Aggarwal P, Kehoe S. Ovarian tumors in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol 2011; 155: 119–24.
12. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117: 742.
13. American College of Obstetricians anf Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100: 1413.
14. Anton C, Carvalho FM, Oliveira EI et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics 2012; 67: 437–41.
15. Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012; 22: 5–8.
16. Behtash N, Karimi Zarchi M et al. Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC Pregnancy Childbirth 2008; 8: 3–10.
17. Chen L, Berek JS, Goff B et al. Ovarian tumors of low malignant potential. http://www.uptodate.com /contents/
18. Coskun A, Kiran G, Ozdemir O. CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 2008; 35 (2): 137–9.
19. Dodge JE, Covens AL, Lacchetti C et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol 2012; 126: 157.
20. Drapkin R, von Horsten HH, Lin Y et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162–9.
21. Duffy MJ, Bonfrer JM, Kulpa J et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15: 679.
22. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010; 56 (2): 327–9.
23. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847–53.
24. Geomini P, Kruitwagen R, Bremer GL et al. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113: 384.
25. Hakansson F, Hodgall EV, Nedergaard L et al. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with pelvic mass. Acta Obstet Gynecol Scand 2012; 91: 496–502.
26. Hellström I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695–700.
27. Hoover K, Jenkins TR. Evaluation and management of adnexal mass in pregnancy. Am J Obstet Gynecol 2011; 97–102.
28. Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315–9.
29. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69.
30. Kadija S, Stefanovic A, Jeremic K et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2012; 22: 238–44.
31. Karlsen MA, Sandhu N, Hodgall C et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass. Gynecol Oncol 2012; 127: 379–83.
32. Kim YM, Whang DH, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011; 49: 527–34.
33. Kumari I, Kaur S, Mohan H, Huria A. Adnexal masses in pregnancy: a 5-year review. Aust N Z J Obstet Gynaecol 2006; 46: 52–4.
34. Leiserowitz G, Xing G et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101: 315–21.
35. Lenhard M, Stieber P, Hertlein L et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011; 49: 2081–8.
36. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013; 167 (1): 81–5.
37. Montagnana M, Danese E, Ruzzenente O et al. The ROMA (The Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011; 49: 521–5.
38. Moore LE, Fung ET, McGuire M et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006; 15: 1641.
39. Moore RG, Jabre-Raughley M, Brown AK et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: 228.e1–6.
40. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40–6.
41. Moore RG, Miller MC, Disilvestro P et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011; 118: 280–8.
42. Moore RG, Miller MC, Eklund EE et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012; 206: 349–54.
43. Muller CY. Doctor, should I get this new ovarian cancer test–OVA1? Obstet Gynecol 2010; 116 (2 Pt 1): 246–7.
44. Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200: 639.
45. Runowicz CD, Brewer M, Goff B, Barss VA. Management of ovarian cancer in pregnant women. http://www.uptodate.com /contents/
46. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44: 151.
47. Ueland FR, Li AJ, Goff B, Falk SJ. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. http://www.uptodate.com /contents/
48. Ueland FR, Desimone CP, Seamon LG et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117: 1289.
49. Using OVA 1. http://www.ova-1.com/physicians/using-ova1
50. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371.
51. Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159–66.
52. Han S, Lotgerink A, Van Calsteren K et al. Physiologic variations of serum markers in gynecological malignancies during pregnancy: a systematic review. BMC Medicine 2012; 10: 86.
53. Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006; 16 (1): 8–15.
2. Алексеева М.Л., Гусарова Е.В., Муллабаева С.М., Понкратов Т.С. Онкомаркеры, их характеристика и некоторые аспекты клинико-диагностического использования. Проблемы репродукции. 2005; 3: 43–5.
3. Ашрафян Л.А., Киселев В.И. Опухоли репродуктивной системы (этиология, патогенез). М.: Димитрейд График Групп, 2007.
4. Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина, 1989.
5. Ильина Л.М. Рак яичников: новое в диагностике и лечении. Информационное письмо ассоциации гинекологов-эндокринологов России №11 от 30.04.2011.
6. Краснопольский В.И., Логутова Л.С., Буянова С.Н. и др. Хирургическая и акушерская тактика при сочетании беременности с опухолями половых органов. Акуш. и гинекол. 2002; 5: 41–5.
7. Магнитская Н.А. Диагностика и лечение образований яичников у беременных. Автореф. дис. ... канд. мед. наук. М., 2012.
8. Савельева Г.М., Бреусенко В.Г., Соломатина А.А. Диагностика опухолей и опухолевидных образований яичников. Рос. вестн. акушера-гинеколога. 2005; 6: 53–61.
9. Серов В.Н., Кудрявцева Л.И. Доброкачественные опухоли и опухолевидные образования яичников. М: Триада-Х, 1999; 149.
10. Урманчеева А.Ф., Кутушева Г.Ф., Ульрих Е.А. Опухоли яичника (клиника, диагностика и лечение). СПб.: Н-Л, 2012.
11. Aggarwal P, Kehoe S. Ovarian tumors in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol 2011; 155: 119–24.
12. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117: 742.
13. American College of Obstetricians anf Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100: 1413.
14. Anton C, Carvalho FM, Oliveira EI et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics 2012; 67: 437–41.
15. Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012; 22: 5–8.
16. Behtash N, Karimi Zarchi M et al. Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC Pregnancy Childbirth 2008; 8: 3–10.
17. Chen L, Berek JS, Goff B et al. Ovarian tumors of low malignant potential. http://www.uptodate.com /contents/
18. Coskun A, Kiran G, Ozdemir O. CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 2008; 35 (2): 137–9.
19. Dodge JE, Covens AL, Lacchetti C et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol 2012; 126: 157.
20. Drapkin R, von Horsten HH, Lin Y et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162–9.
21. Duffy MJ, Bonfrer JM, Kulpa J et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15: 679.
22. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010; 56 (2): 327–9.
23. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847–53.
24. Geomini P, Kruitwagen R, Bremer GL et al. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113: 384.
25. Hakansson F, Hodgall EV, Nedergaard L et al. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with pelvic mass. Acta Obstet Gynecol Scand 2012; 91: 496–502.
26. Hellström I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695–700.
27. Hoover K, Jenkins TR. Evaluation and management of adnexal mass in pregnancy. Am J Obstet Gynecol 2011; 97–102.
28. Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315–9.
29. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69.
30. Kadija S, Stefanovic A, Jeremic K et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2012; 22: 238–44.
31. Karlsen MA, Sandhu N, Hodgall C et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass. Gynecol Oncol 2012; 127: 379–83.
32. Kim YM, Whang DH, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011; 49: 527–34.
33. Kumari I, Kaur S, Mohan H, Huria A. Adnexal masses in pregnancy: a 5-year review. Aust N Z J Obstet Gynaecol 2006; 46: 52–4.
34. Leiserowitz G, Xing G et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101: 315–21.
35. Lenhard M, Stieber P, Hertlein L et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011; 49: 2081–8.
36. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013; 167 (1): 81–5.
37. Montagnana M, Danese E, Ruzzenente O et al. The ROMA (The Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011; 49: 521–5.
38. Moore LE, Fung ET, McGuire M et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006; 15: 1641.
39. Moore RG, Jabre-Raughley M, Brown AK et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: 228.e1–6.
40. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40–6.
41. Moore RG, Miller MC, Disilvestro P et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011; 118: 280–8.
42. Moore RG, Miller MC, Eklund EE et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012; 206: 349–54.
43. Muller CY. Doctor, should I get this new ovarian cancer test–OVA1? Obstet Gynecol 2010; 116 (2 Pt 1): 246–7.
44. Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200: 639.
45. Runowicz CD, Brewer M, Goff B, Barss VA. Management of ovarian cancer in pregnant women. http://www.uptodate.com /contents/
46. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44: 151.
47. Ueland FR, Li AJ, Goff B, Falk SJ. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. http://www.uptodate.com /contents/
48. Ueland FR, Desimone CP, Seamon LG et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117: 1289.
49. Using OVA 1. http://www.ova-1.com/physicians/using-ova1
50. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371.
51. Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159–66.
52. Han S, Lotgerink A, Van Calsteren K et al. Physiologic variations of serum markers in gynecological malignancies during pregnancy: a systematic review. BMC Medicine 2012; 10: 86.
53. Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006; 16 (1): 8–15.
2. Алексеева М.Л., Гусарова Е.В., Муллабаева С.М., Понкратов Т.С. Онкомаркеры, их характеристика и некоторые аспекты клинико-диагностического использования. Проблемы репродукции. 2005; 3: 43–5.
3. Ашрафян Л.А., Киселев В.И. Опухоли репродуктивной системы (этиология, патогенез). М.: Димитрейд График Групп, 2007.
4. Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина, 1989.
5. Ильина Л.М. Рак яичников: новое в диагностике и лечении. Информационное письмо ассоциации гинекологов-эндокринологов России №11 от 30.04.2011.
6. Краснопольский В.И., Логутова Л.С., Буянова С.Н. и др. Хирургическая и акушерская тактика при сочетании беременности с опухолями половых органов. Акуш. и гинекол. 2002; 5: 41–5.
7. Магнитская Н.А. Диагностика и лечение образований яичников у беременных. Автореф. дис. ... канд. мед. наук. М., 2012.
8. Савельева Г.М., Бреусенко В.Г., Соломатина А.А. Диагностика опухолей и опухолевидных образований яичников. Рос. вестн. акушера-гинеколога. 2005; 6: 53–61.
9. Серов В.Н., Кудрявцева Л.И. Доброкачественные опухоли и опухолевидные образования яичников. М: Триада-Х, 1999; 149.
10. Урманчеева А.Ф., Кутушева Г.Ф., Ульрих Е.А. Опухоли яичника (клиника, диагностика и лечение). СПб.: Н-Л, 2012.
11. Aggarwal P, Kehoe S. Ovarian tumors in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol 2011; 155: 119–24.
12. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117: 742.
13. American College of Obstetricians anf Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100: 1413.
14. Anton C, Carvalho FM, Oliveira EI et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics 2012; 67: 437–41.
15. Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012; 22: 5–8.
16. Behtash N, Karimi Zarchi M et al. Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC Pregnancy Childbirth 2008; 8: 3–10.
17. Chen L, Berek JS, Goff B et al. Ovarian tumors of low malignant potential. http://www.uptodate.com /contents/
18. Coskun A, Kiran G, Ozdemir O. CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 2008; 35 (2): 137–9.
19. Dodge JE, Covens AL, Lacchetti C et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol 2012; 126: 157.
20. Drapkin R, von Horsten HH, Lin Y et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162–9.
21. Duffy MJ, Bonfrer JM, Kulpa J et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15: 679.
22. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010; 56 (2): 327–9.
23. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847–53.
24. Geomini P, Kruitwagen R, Bremer GL et al. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113: 384.
25. Hakansson F, Hodgall EV, Nedergaard L et al. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with pelvic mass. Acta Obstet Gynecol Scand 2012; 91: 496–502.
26. Hellström I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695–700.
27. Hoover K, Jenkins TR. Evaluation and management of adnexal mass in pregnancy. Am J Obstet Gynecol 2011; 97–102.
28. Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315–9.
29. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69.
30. Kadija S, Stefanovic A, Jeremic K et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2012; 22: 238–44.
31. Karlsen MA, Sandhu N, Hodgall C et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass. Gynecol Oncol 2012; 127: 379–83.
32. Kim YM, Whang DH, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011; 49: 527–34.
33. Kumari I, Kaur S, Mohan H, Huria A. Adnexal masses in pregnancy: a 5-year review. Aust N Z J Obstet Gynaecol 2006; 46: 52–4.
34. Leiserowitz G, Xing G et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101: 315–21.
35. Lenhard M, Stieber P, Hertlein L et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011; 49: 2081–8.
36. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013; 167 (1): 81–5.
37. Montagnana M, Danese E, Ruzzenente O et al. The ROMA (The Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011; 49: 521–5.
38. Moore LE, Fung ET, McGuire M et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006; 15: 1641.
39. Moore RG, Jabre-Raughley M, Brown AK et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: 228.e1–6.
40. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40–6.
41. Moore RG, Miller MC, Disilvestro P et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011; 118: 280–8.
42. Moore RG, Miller MC, Eklund EE et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012; 206: 349–54.
43. Muller CY. Doctor, should I get this new ovarian cancer test–OVA1? Obstet Gynecol 2010; 116 (2 Pt 1): 246–7.
44. Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200: 639.
45. Runowicz CD, Brewer M, Goff B, Barss VA. Management of ovarian cancer in pregnant women. http://www.uptodate.com /contents/
46. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44: 151.
47. Ueland FR, Li AJ, Goff B, Falk SJ. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. http://www.uptodate.com /contents/
48. Ueland FR, Desimone CP, Seamon LG et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117: 1289.
49. Using OVA 1. http://www.ova-1.com/physicians/using-ova1
50. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371.
51. Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159–66.
52. Han S, Lotgerink A, Van Calsteren K et al. Physiologic variations of serum markers in gynecological malignancies during pregnancy: a systematic review. BMC Medicine 2012; 10: 86.
53. Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006; 16 (1): 8–15.
________________________________________________
2. Алексеева М.Л., Гусарова Е.В., Муллабаева С.М., Понкратов Т.С. Онкомаркеры, их характеристика и некоторые аспекты клинико-диагностического использования. Проблемы репродукции. 2005; 3: 43–5.
3. Ашрафян Л.А., Киселев В.И. Опухоли репродуктивной системы (этиология, патогенез). М.: Димитрейд График Групп, 2007.
4. Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина, 1989.
5. Ильина Л.М. Рак яичников: новое в диагностике и лечении. Информационное письмо ассоциации гинекологов-эндокринологов России №11 от 30.04.2011.
6. Краснопольский В.И., Логутова Л.С., Буянова С.Н. и др. Хирургическая и акушерская тактика при сочетании беременности с опухолями половых органов. Акуш. и гинекол. 2002; 5: 41–5.
7. Магнитская Н.А. Диагностика и лечение образований яичников у беременных. Автореф. дис. ... канд. мед. наук. М., 2012.
8. Савельева Г.М., Бреусенко В.Г., Соломатина А.А. Диагностика опухолей и опухолевидных образований яичников. Рос. вестн. акушера-гинеколога. 2005; 6: 53–61.
9. Серов В.Н., Кудрявцева Л.И. Доброкачественные опухоли и опухолевидные образования яичников. М: Триада-Х, 1999; 149.
10. Урманчеева А.Ф., Кутушева Г.Ф., Ульрих Е.А. Опухоли яичника (клиника, диагностика и лечение). СПб.: Н-Л, 2012.
11. Aggarwal P, Kehoe S. Ovarian tumors in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol 2011; 155: 119–24.
12. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117: 742.
13. American College of Obstetricians anf Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100: 1413.
14. Anton C, Carvalho FM, Oliveira EI et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics 2012; 67: 437–41.
15. Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012; 22: 5–8.
16. Behtash N, Karimi Zarchi M et al. Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC Pregnancy Childbirth 2008; 8: 3–10.
17. Chen L, Berek JS, Goff B et al. Ovarian tumors of low malignant potential. http://www.uptodate.com /contents/
18. Coskun A, Kiran G, Ozdemir O. CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 2008; 35 (2): 137–9.
19. Dodge JE, Covens AL, Lacchetti C et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol 2012; 126: 157.
20. Drapkin R, von Horsten HH, Lin Y et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162–9.
21. Duffy MJ, Bonfrer JM, Kulpa J et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15: 679.
22. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010; 56 (2): 327–9.
23. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847–53.
24. Geomini P, Kruitwagen R, Bremer GL et al. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113: 384.
25. Hakansson F, Hodgall EV, Nedergaard L et al. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with pelvic mass. Acta Obstet Gynecol Scand 2012; 91: 496–502.
26. Hellström I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695–700.
27. Hoover K, Jenkins TR. Evaluation and management of adnexal mass in pregnancy. Am J Obstet Gynecol 2011; 97–102.
28. Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315–9.
29. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69.
30. Kadija S, Stefanovic A, Jeremic K et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2012; 22: 238–44.
31. Karlsen MA, Sandhu N, Hodgall C et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass. Gynecol Oncol 2012; 127: 379–83.
32. Kim YM, Whang DH, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011; 49: 527–34.
33. Kumari I, Kaur S, Mohan H, Huria A. Adnexal masses in pregnancy: a 5-year review. Aust N Z J Obstet Gynaecol 2006; 46: 52–4.
34. Leiserowitz G, Xing G et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101: 315–21.
35. Lenhard M, Stieber P, Hertlein L et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011; 49: 2081–8.
36. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013; 167 (1): 81–5.
37. Montagnana M, Danese E, Ruzzenente O et al. The ROMA (The Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011; 49: 521–5.
38. Moore LE, Fung ET, McGuire M et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006; 15: 1641.
39. Moore RG, Jabre-Raughley M, Brown AK et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: 228.e1–6.
40. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40–6.
41. Moore RG, Miller MC, Disilvestro P et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011; 118: 280–8.
42. Moore RG, Miller MC, Eklund EE et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012; 206: 349–54.
43. Muller CY. Doctor, should I get this new ovarian cancer test–OVA1? Obstet Gynecol 2010; 116 (2 Pt 1): 246–7.
44. Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200: 639.
45. Runowicz CD, Brewer M, Goff B, Barss VA. Management of ovarian cancer in pregnant women. http://www.uptodate.com /contents/
46. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44: 151.
47. Ueland FR, Li AJ, Goff B, Falk SJ. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. http://www.uptodate.com /contents/
48. Ueland FR, Desimone CP, Seamon LG et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117: 1289.
49. Using OVA 1. http://www.ova-1.com/physicians/using-ova1
50. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371.
51. Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159–66.
52. Han S, Lotgerink A, Van Calsteren K et al. Physiologic variations of serum markers in gynecological malignancies during pregnancy: a systematic review. BMC Medicine 2012; 10: 86.
53. Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006; 16 (1): 8–15.
Авторы
С.А.Мартынов
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.